Skip to main content

AEON Biopharma, Inc.

AEON
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001837607

In the last 90 days, AEON Biopharma, Inc. insiders filed 3 open-market purchases and 0 sales; 28 institutions reported holding it in 13F filings for Q3 2026, worth $18.7M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$10.3M
Insider buysLast 90 days, $57.1K in total
3
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +6 vs. previous quarter
28
13F valueReported value at the end of Q3 2026
$18.7M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$39.2M
−193.4% year over year
Free cash flow, FY2025
-$17.3M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
2.66M
Shares sold short
Change
−589.2K
−18.1% vs. previous
Days to cover
6.40
At average daily volume

Superinvestors holding AEON, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding AEON at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by AEON Biopharma, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 20, 2026 (view filing)5:11 PM ETNov 20Same dayWilson Alexander BlairCLO, CSO and Corp SecretaryPPurchaseClass A Common Stock+135.7K$0.1288+$17.5K+6.2%2.32M after
Nov 20, 2026 (view filing)5:10 PM ETNov 191 daySy JenniferChief Accounting OfficerPPurchaseClass A Common Stock+153.8K$0.1299+$20.0K+10.2%1.66M after
Nov 20, 2026 (view filing)5:08 PM ETNov 191 dayBancroft Robert E.President and CEOPPurchaseClass A Common Stock+152.3K$0.1286+$19.6K+4.8%3.33M after
Aug 21, 2026 (view filing)7:41 PM ETAug 192 daysLynch Timothy P10% OwnerPPurchaseClass A Common Stock+1.15M$0.2117+$243.5K+21.5%6.50M after
May 23, 2025 (view filing)4:46 PM ETMay 212 daysFischer JostDirectorPPurchaseClass A Common Stock+60.0K$0.4875+$29.3K+29.0%266.8K after
May 21, 2025 (view filing)May 19-202 daysFischer JostDirectorPPurchaseClass A Common Stock+110.0K$0.5055+$55.6K+113.7%206.8K after2 lots
Aug 14, 2023 (view filing)Aug 113 daysStrathspey Crown Holdings Group, LLC10% OwnerSSaleClass A Common Stock−7.38M$10.00−$73.8M−78.4%2.03M after

Top 10 13F holders, Q3 2026

See all 28 holders

The largest institutional positions in AEON Biopharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding AEON in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Dauntless Investment Group, LLC51,734,490$15.5M28.43%+39,244,336+314.2%Added
Nantahala Capital Management, LLC4,400,000$1.30M0.07%+4,400,000New
Ikarian Capital, LLC2,203,406$661.0K0.13%+2,203,406New
Stonepine Capital Management, LLC2,125,748$637.7K0.53%+2,125,748New
Boothbay Fund Management, LLC703,865$211.2K0.00%+703,865New
DG Capital Management, LLC259,146$77.7K0.03%+259,146New
Jane Street Group, LLC249,762$74.9K0.00%+249,762New
Vanguard Fiduciary Trust Co214,725$64.4K0.00%+201,012+1,465.8%Added
Geode Capital Management, LLC95,311$28.6K0.00%00.0%Unchanged
Vanguard Capital Management LLC90,529$27.2K0.00%00.0%Unchanged

Holders of 5% or more of AEON

See all 10 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of AEON Biopharma, Inc..

Largest holders of AEON from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Daewoong Co., Ltd13D49.99%12.0M shares+49.09 ppfrom 0.90%Jul 28, 20233 filingsJan 29, 2026SEC
Daewoong Co., Ltd13D/A30.60%23.2M shares–Nov 10, 20261 filingNov 10, 2026SEC
Lynch Timothy P13G13.00%6.50M sharesNewAug 21, 20261 filingAug 21, 2026SEC
Nantahala Capital Management, LLC13G9.99%5.05M sharesNewNov 13, 20261 filingNov 13, 2026SEC
Ikarian Capital, LLC13G9.90%7.36M sharesNewNov 16, 20261 filingNov 16, 2026SEC